{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:08:26Z","timestamp":1788736106957,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctrv.2026.103178","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:17:12Z","timestamp":1782400632000},"page":"103178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Distinct outcome patterns according to RAS and BRAF status in MSI-H\/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"149","author":[{"given":"Andrea","family":"Pretta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Giampieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bottelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Taravella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Intini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pina","family":"Ziranu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Manoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Maddalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Locci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Donisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariapaola","family":"Masiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Caschili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Pasquinucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Maccioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sperotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ctrv.2026.103178_bb0005","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.ctrv.2026.103178_bb0010","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le DT","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103178_bb0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"issue":"6349","key":"10.1016\/j.ctrv.2026.103178_bb0020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103178_bb0025","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal Cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103178_bb0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal Cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103178_bb0035","article-title":"Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H\/dMMR metastatic colorectal cancer","volume":"36","author":"Amonkar","year":"2023","journal-title":"Cancer Treat Res Commun"},{"issue":"7407","key":"10.1016\/j.ctrv.2026.103178_bb0040","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103178_bb0045","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103178_bb0050","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.3390\/cimb45100491","article-title":"Molecular pattern and clinical implications of KRAS\/NRAS and BRAF mutations in colorectal cancer","volume":"45","author":"G\u00f6kmen","year":"2023","journal-title":"Curr Issues Mol Biol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103178_bb0055","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103178_bb0060","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal Cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103178_bb0065","doi-asserted-by":"crossref","unstructured":"Andr\u00e9, Thierry et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet, 405, 10476, 383\u2013395.","DOI":"10.1016\/S0140-6736(24)02848-4"},{"key":"10.1016\/j.ctrv.2026.103178_bb0070","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2023.02.016","article-title":"Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164","volume":"186","author":"Le","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103178_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010598","article-title":"Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors","volume":"13","author":"Nasca","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103178_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113495","article-title":"Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - outcome and novel predictive markers","volume":"198","author":"Stemmer","year":"2024","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103178_bb0085","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1158\/2767-9764.CRC-23-0340","article-title":"Sustained disease control in immune checkpoint blockade responders with microsatellite instability-high colorectal cancer after treatment termination","volume":"3","author":"Simmons","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.ctrv.2026.103178_bb0090","article-title":"Comparison of survival outcomes for patients with Lynch vs non-Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103178_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114290","article-title":"BRAF + EGFR +\/\u2212 MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer","volume":"210","author":"Ambrosini","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103178_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010424","article-title":"Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors","volume":"13","author":"Taieb","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103178_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001499","article-title":"RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study","volume":"8","author":"Cohen","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103178_bb0110","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jamaoncol.2023.2761","article-title":"Avelumab vs standard second-line chemotherapy in patients with metastatic colorectal cancer and microsatellite instability: a randomized clinical trial","volume":"9","author":"Ta\u00efeb","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103178_bb0115","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","article-title":"Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms","volume":"121","author":"Sahin","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103178_bb0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejca.2023.03.029","article-title":"Tumour mutational burden as a biomarker in patients with mismatch repair deficient\/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors","volume":"187","author":"Manca","year":"2023","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103178_bb0125","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103178_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103178_bb0135","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fon-2022-1249","article-title":"SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H\/dMMR BRAFV600E-mutant mCRC","volume":"20","author":"Elez","year":"2024","journal-title":"Future Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:30:26Z","timestamp":1788733826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S0305737226000927"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103178","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct outcome patterns according to RAS and BRAF status in MSI-H\/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103178"}}